Newsletter
The Oracle Cancer Trust Peter Rhys Evans Scholarship
Oracle Cancer Trust is delighted to announce a new scholarship scheme for senior Head and Neck Cancer TraineesĀ Oracle Cancer Trust is delighted to announce a new scholarship scheme for…
Read More
HPV Coalition launch
Oracle Cancer Trust is pleased to announce its membership of the UK HPV Coalition. HPV affects >80% of people in their lifetime and causes cancers affecting both males and females:…
Read More
Robotic surgery trial yields exciting results for head and neck cancer patients
Robotic surgery can improve survival rates and reduce recovery time for some people with recurrent head and neck cancers, suggests a pioneering new international study led by researchers at The Royal Marsden NHS Foundation Trust.
Read More
Leading head and neck surgeon to appear in TV series
Leading head and neck surgeon and authority on robotic surgery will be appearing in a three-party Channel 4 series “Super Surgeons – A Chance at Life”
Read More
Over 140,000 sign up for NHS Trial
A major new NHS Trial aims to discover hard to diagnose cancers early using a simple blood test
Read More
Tribute to Peter Rhys Evans
The team at Oracle Cancer Trust are saddened to announce the passing of Chairman and Founder Peter Rhys Evans
Read More
MR-Linac machine reduces radiotherapy treatment time
MR Linac, a new revolutionary cancer treatment machine can halve radiotherapy treatment time and has shown to be 99.9 per cent accurate for head and neck cancer patients.
Read More
Funding available for inequalities project
Oracle Cancer Trust and North West Cancer Research have announced a new grant funding opportunity to tackle inequalities in Head and Neck Cancer
Read More
Oracle joins other head and neck charities to support Ukrainian arrivals
Oracle Cancer Trust has joined forces with other head and neck cancer charities in the UK to support Ukranians arriving that need and and support for head and neck cancer
Read More
New test can personalise head and neck cancer treatments
Research has shown patients can benefit from personalised immuno and chemotherapy treatments based on their levels of a key immune protein
Read More